Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Study sponsor: Arrowhead Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-12Actual
Enrollment · participants12Actual
Source updated2026-01-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.